Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 691 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$291.19M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$297.62M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$291.48M
Net Profit Margin
-103.29%
TTM Avg
-83.69%
3Y Avg
-107.92%
5Y Avg
-85.90%
Market Cap
$288.54M
Net Profit Margin
-246.42%
TTM Avg
611.54%
3Y Avg
-783.13%
5Y Avg
-1134.34%
Market Cap
$304.72M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-6520.67%
5Y Avg
-12425.66%
Market Cap
$287.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$310.71M
Net Profit Margin
-145.12%
TTM Avg
-145.12%
3Y Avg
-145.12%
5Y Avg
-145.12%
Market Cap
$283.44M
Net Profit Margin
0.00%
TTM Avg
-6.08%
3Y Avg
-1303.66%
5Y Avg
-1073.20%
Market Cap
$280.29M
Net Profit Margin
-38.13%
TTM Avg
-18.76%
3Y Avg
-107.01%
5Y Avg
-249.44%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $291.19M | 0.00% | 0.00% | 0.00% | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Standard BioTools Inc. (LAB)vs › | $291.48M | -103.29% | -83.69% | -107.92% | -85.90% |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.54M | -246.42% | 611.54% | -783.13% | -1134.34% |
| Benitec Biopharma Inc. (BNTC)vs › | $304.72M | 0.00% | 0.00% | -6520.67% | -12425.66% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $310.71M | -145.12% | -145.12% | -145.12% | -145.12% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.44M | 0.00% | -6.08% | -1303.66% | -1073.20% |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | -38.13% | -18.76% | -107.01% | -249.44% |
| Fate Therapeutics, Inc. (FATE)vs › | $278.58M | -1941.09% | -1708.77% | -990.85% | -815.81% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2022-12-31 | 0.00% |
